KTICMonsanto Bets on Next Phase of High-Tech CropsKTICOver the past year, Monsanto has licensed two different Crispr versions, Crispr-Cas and Crispr-Cpf1, as well as the Exzact technology and another gene-editing platform developed by TargetGene Biotec… Continue reading
Endpoints News |
One of Kite Pharma’s CAR–T patients died from cerebral edema, triggering a safety alarm
Endpoints News Kite Pharma revealed today that one of the patients in their late-stage program for the CAR-T drug KTE-C19 died from cerebral edema, the same brain swelling condition that went on to scuttle Juno Therapeutics’ lead drug. In a call with analysts for … Kite Pharma Discloses CAR–T Patient Death, Rattling InvestorsTheStreet.com Here’s Why Kite Pharma (KITE) Stock Is Plummeting TodayNasdaq Here’s What’s Dragging Kite Pharma Inc. Down TodayMotley Fool Market Exclusive –Highland Mirror all 45 news articles » |
|
Tau Immunotherapy Shows Great Potential in Pre-Clinical Studies
PR Newswire (press release) Anti-Aβ immunotherapy is considered one of the most promising AD treatments under investigation, and is currently being tested in many clinical trials. Unfortunately, none of the attempts reported to date have shown a positive clinical outcome in … |
|
Tau Immunotherapy Shows Great Potential in Pre-Clinical Studies
PR Newswire (press release) Anti-Aβ immunotherapy is considered one of the most promising AD treatments under investigation, and is currently being tested in many clinical trials. Unfortunately, none of the attempts reported to date have shown a positive clinical outcome in … |
TheStreet.com |
Kite Pharma Discloses CAR–T Patient Death, Rattling Investors
TheStreet.com CAR-T is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant blood cancer cells. CAR-T is highly effective at eliminating cancer cells in patients no longer responsive to … Kite Pharma Inc (NASDAQ:KITE) reported earnings of ($1.28) per share missing Walls Streets expectations.Market Exclusive |
TheStreet.com |
Kite Pharma Discloses CAR–T Patient Death, Rattling Investors
TheStreet.com CAR-T is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant blood cancer cells. CAR-T is highly effective at eliminating cancer cells in patients no longer responsive to … Kite Pharma Inc (NASDAQ:KITE) reported earnings of ($1.28) per share missing Walls Streets expectations.Market Exclusive |